nodes	percent_of_prediction	percent_of_DWPC	metapath
Betaxolol—CYP1A2—Sorafenib—liver cancer	0.0987	0.43	CbGbCtD
Betaxolol—CYP2D6—Sorafenib—liver cancer	0.0813	0.355	CbGbCtD
Betaxolol—CYP2D6—Doxorubicin—liver cancer	0.0494	0.215	CbGbCtD
Betaxolol—Dyspepsia—Sorafenib—liver cancer	0.00187	0.00268	CcSEcCtD
Betaxolol—Decreased appetite—Sorafenib—liver cancer	0.00184	0.00265	CcSEcCtD
Betaxolol—Thrombophlebitis—Epirubicin—liver cancer	0.00184	0.00264	CcSEcCtD
Betaxolol—Bladder pain—Doxorubicin—liver cancer	0.00184	0.00264	CcSEcCtD
Betaxolol—Mouth ulceration—Doxorubicin—liver cancer	0.00184	0.00264	CcSEcCtD
Betaxolol—Diabetes mellitus—Epirubicin—liver cancer	0.00183	0.00263	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Sorafenib—liver cancer	0.00183	0.00263	CcSEcCtD
Betaxolol—Fatigue—Sorafenib—liver cancer	0.00183	0.00262	CcSEcCtD
Betaxolol—Pain—Sorafenib—liver cancer	0.00181	0.0026	CcSEcCtD
Betaxolol—Constipation—Sorafenib—liver cancer	0.00181	0.0026	CcSEcCtD
Betaxolol—Vascular purpura—Epirubicin—liver cancer	0.00178	0.00256	CcSEcCtD
Betaxolol—Hypertonia—Doxorubicin—liver cancer	0.00178	0.00256	CcSEcCtD
Betaxolol—Eczema—Epirubicin—liver cancer	0.00177	0.00255	CcSEcCtD
Betaxolol—Abnormal vision—Doxorubicin—liver cancer	0.00177	0.00254	CcSEcCtD
Betaxolol—Eye pain—Epirubicin—liver cancer	0.00177	0.00253	CcSEcCtD
Betaxolol—Mental disability—Doxorubicin—liver cancer	0.00176	0.00253	CcSEcCtD
Betaxolol—Lymphadenopathy—Doxorubicin—liver cancer	0.00173	0.00248	CcSEcCtD
Betaxolol—Thrombophlebitis—Doxorubicin—liver cancer	0.0017	0.00245	CcSEcCtD
Betaxolol—Increased appetite—Epirubicin—liver cancer	0.0017	0.00244	CcSEcCtD
Betaxolol—Diabetes mellitus—Doxorubicin—liver cancer	0.0017	0.00243	CcSEcCtD
Betaxolol—Urticaria—Sorafenib—liver cancer	0.00168	0.00242	CcSEcCtD
Betaxolol—Body temperature increased—Sorafenib—liver cancer	0.00168	0.00241	CcSEcCtD
Betaxolol—Renal impairment—Epirubicin—liver cancer	0.00168	0.0024	CcSEcCtD
Betaxolol—Purpura—Epirubicin—liver cancer	0.00165	0.00237	CcSEcCtD
Betaxolol—Vascular purpura—Doxorubicin—liver cancer	0.00165	0.00237	CcSEcCtD
Betaxolol—Eczema—Doxorubicin—liver cancer	0.00164	0.00236	CcSEcCtD
Betaxolol—Eye pain—Doxorubicin—liver cancer	0.00163	0.00235	CcSEcCtD
Betaxolol—Cardiac failure—Epirubicin—liver cancer	0.00163	0.00234	CcSEcCtD
Betaxolol—Hypoglycaemia—Epirubicin—liver cancer	0.00163	0.00234	CcSEcCtD
Betaxolol—Lethargy—Epirubicin—liver cancer	0.00163	0.00234	CcSEcCtD
Betaxolol—Osteoarthritis—Epirubicin—liver cancer	0.00159	0.00229	CcSEcCtD
Betaxolol—Increased appetite—Doxorubicin—liver cancer	0.00157	0.00225	CcSEcCtD
Betaxolol—Affect lability—Epirubicin—liver cancer	0.00157	0.00225	CcSEcCtD
Betaxolol—Hypersensitivity—Sorafenib—liver cancer	0.00156	0.00224	CcSEcCtD
Betaxolol—Renal impairment—Doxorubicin—liver cancer	0.00155	0.00222	CcSEcCtD
Betaxolol—Purpura—Doxorubicin—liver cancer	0.00153	0.0022	CcSEcCtD
Betaxolol—Asthenia—Sorafenib—liver cancer	0.00152	0.00218	CcSEcCtD
Betaxolol—Cardiac failure—Doxorubicin—liver cancer	0.00151	0.00217	CcSEcCtD
Betaxolol—Hypoglycaemia—Doxorubicin—liver cancer	0.00151	0.00217	CcSEcCtD
Betaxolol—Mood swings—Epirubicin—liver cancer	0.00151	0.00217	CcSEcCtD
Betaxolol—Lethargy—Doxorubicin—liver cancer	0.00151	0.00216	CcSEcCtD
Betaxolol—Pruritus—Sorafenib—liver cancer	0.0015	0.00215	CcSEcCtD
Betaxolol—Ataxia—Epirubicin—liver cancer	0.0015	0.00215	CcSEcCtD
Betaxolol—Osteoarthritis—Doxorubicin—liver cancer	0.00148	0.00212	CcSEcCtD
Betaxolol—Affect lability—Doxorubicin—liver cancer	0.00145	0.00208	CcSEcCtD
Betaxolol—Hypokalaemia—Epirubicin—liver cancer	0.00145	0.00208	CcSEcCtD
Betaxolol—Diarrhoea—Sorafenib—liver cancer	0.00145	0.00208	CcSEcCtD
Betaxolol—Breast disorder—Epirubicin—liver cancer	0.00144	0.00207	CcSEcCtD
Betaxolol—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.00144	0.00206	CcSEcCtD
Betaxolol—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.00144	0.00206	CcSEcCtD
Betaxolol—Nasopharyngitis—Epirubicin—liver cancer	0.00143	0.00205	CcSEcCtD
Betaxolol—Alanine aminotransferase increased—Epirubicin—liver cancer	0.00141	0.00202	CcSEcCtD
Betaxolol—Dizziness—Sorafenib—liver cancer	0.0014	0.00201	CcSEcCtD
Betaxolol—Mood swings—Doxorubicin—liver cancer	0.0014	0.00201	CcSEcCtD
Betaxolol—Ataxia—Doxorubicin—liver cancer	0.00139	0.00199	CcSEcCtD
Betaxolol—Asthma—Epirubicin—liver cancer	0.00138	0.00198	CcSEcCtD
Betaxolol—Dysphagia—Epirubicin—liver cancer	0.00138	0.00198	CcSEcCtD
Betaxolol—Influenza—Epirubicin—liver cancer	0.00138	0.00198	CcSEcCtD
Betaxolol—Vomiting—Sorafenib—liver cancer	0.00135	0.00194	CcSEcCtD
Betaxolol—Hypokalaemia—Doxorubicin—liver cancer	0.00134	0.00193	CcSEcCtD
Betaxolol—Angina pectoris—Epirubicin—liver cancer	0.00134	0.00193	CcSEcCtD
Betaxolol—Rash—Sorafenib—liver cancer	0.00134	0.00192	CcSEcCtD
Betaxolol—Dermatitis—Sorafenib—liver cancer	0.00134	0.00192	CcSEcCtD
Betaxolol—Breast disorder—Doxorubicin—liver cancer	0.00133	0.00191	CcSEcCtD
Betaxolol—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.00133	0.00191	CcSEcCtD
Betaxolol—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.00133	0.00191	CcSEcCtD
Betaxolol—Headache—Sorafenib—liver cancer	0.00133	0.00191	CcSEcCtD
Betaxolol—Bronchitis—Epirubicin—liver cancer	0.00133	0.0019	CcSEcCtD
Betaxolol—Nasopharyngitis—Doxorubicin—liver cancer	0.00132	0.00189	CcSEcCtD
Betaxolol—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.0013	0.00187	CcSEcCtD
Betaxolol—Dysuria—Epirubicin—liver cancer	0.00129	0.00185	CcSEcCtD
Betaxolol—Upper respiratory tract infection—Epirubicin—liver cancer	0.00128	0.00184	CcSEcCtD
Betaxolol—Asthma—Doxorubicin—liver cancer	0.00127	0.00183	CcSEcCtD
Betaxolol—Dysphagia—Doxorubicin—liver cancer	0.00127	0.00183	CcSEcCtD
Betaxolol—Influenza—Doxorubicin—liver cancer	0.00127	0.00183	CcSEcCtD
Betaxolol—Nausea—Sorafenib—liver cancer	0.00126	0.00181	CcSEcCtD
Betaxolol—Weight increased—Epirubicin—liver cancer	0.00125	0.0018	CcSEcCtD
Betaxolol—Weight decreased—Epirubicin—liver cancer	0.00125	0.00179	CcSEcCtD
Betaxolol—Hyperglycaemia—Epirubicin—liver cancer	0.00124	0.00178	CcSEcCtD
Betaxolol—Angina pectoris—Doxorubicin—liver cancer	0.00124	0.00178	CcSEcCtD
Betaxolol—Pneumonia—Epirubicin—liver cancer	0.00124	0.00177	CcSEcCtD
Betaxolol—Infestation NOS—Epirubicin—liver cancer	0.00123	0.00176	CcSEcCtD
Betaxolol—Infestation—Epirubicin—liver cancer	0.00123	0.00176	CcSEcCtD
Betaxolol—Bronchitis—Doxorubicin—liver cancer	0.00123	0.00176	CcSEcCtD
Betaxolol—Neuropathy peripheral—Epirubicin—liver cancer	0.0012	0.00173	CcSEcCtD
Betaxolol—Stomatitis—Epirubicin—liver cancer	0.0012	0.00172	CcSEcCtD
Betaxolol—Conjunctivitis—Epirubicin—liver cancer	0.00119	0.00171	CcSEcCtD
Betaxolol—Dysuria—Doxorubicin—liver cancer	0.00119	0.00171	CcSEcCtD
Betaxolol—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00118	0.0017	CcSEcCtD
Betaxolol—Sweating—Epirubicin—liver cancer	0.00118	0.00169	CcSEcCtD
Betaxolol—Weight increased—Doxorubicin—liver cancer	0.00116	0.00167	CcSEcCtD
Betaxolol—Epistaxis—Epirubicin—liver cancer	0.00116	0.00166	CcSEcCtD
Betaxolol—Weight decreased—Doxorubicin—liver cancer	0.00115	0.00166	CcSEcCtD
Betaxolol—Sinusitis—Epirubicin—liver cancer	0.00115	0.00165	CcSEcCtD
Betaxolol—Hyperglycaemia—Doxorubicin—liver cancer	0.00115	0.00165	CcSEcCtD
Betaxolol—Agranulocytosis—Epirubicin—liver cancer	0.00115	0.00165	CcSEcCtD
Betaxolol—Pneumonia—Doxorubicin—liver cancer	0.00114	0.00164	CcSEcCtD
Betaxolol—Infestation NOS—Doxorubicin—liver cancer	0.00114	0.00163	CcSEcCtD
Betaxolol—Infestation—Doxorubicin—liver cancer	0.00114	0.00163	CcSEcCtD
Betaxolol—Bradycardia—Epirubicin—liver cancer	0.00112	0.00161	CcSEcCtD
Betaxolol—Neuropathy peripheral—Doxorubicin—liver cancer	0.00111	0.0016	CcSEcCtD
Betaxolol—Stomatitis—Doxorubicin—liver cancer	0.00111	0.00159	CcSEcCtD
Betaxolol—Rhinitis—Epirubicin—liver cancer	0.00111	0.00159	CcSEcCtD
Betaxolol—Conjunctivitis—Doxorubicin—liver cancer	0.0011	0.00159	CcSEcCtD
Betaxolol—Hypoaesthesia—Epirubicin—liver cancer	0.0011	0.00158	CcSEcCtD
Betaxolol—Pharyngitis—Epirubicin—liver cancer	0.00109	0.00157	CcSEcCtD
Betaxolol—Sweating—Doxorubicin—liver cancer	0.00109	0.00156	CcSEcCtD
Betaxolol—Epistaxis—Doxorubicin—liver cancer	0.00107	0.00154	CcSEcCtD
Betaxolol—Sinusitis—Doxorubicin—liver cancer	0.00107	0.00153	CcSEcCtD
Betaxolol—Visual impairment—Epirubicin—liver cancer	0.00106	0.00153	CcSEcCtD
Betaxolol—Agranulocytosis—Doxorubicin—liver cancer	0.00106	0.00152	CcSEcCtD
Betaxolol—Bradycardia—Doxorubicin—liver cancer	0.00104	0.00149	CcSEcCtD
Betaxolol—Eye disorder—Epirubicin—liver cancer	0.00103	0.00148	CcSEcCtD
Betaxolol—Tinnitus—Epirubicin—liver cancer	0.00103	0.00148	CcSEcCtD
Betaxolol—Flushing—Epirubicin—liver cancer	0.00102	0.00147	CcSEcCtD
Betaxolol—Cardiac disorder—Epirubicin—liver cancer	0.00102	0.00147	CcSEcCtD
Betaxolol—Rhinitis—Doxorubicin—liver cancer	0.00102	0.00147	CcSEcCtD
Betaxolol—Hypoaesthesia—Doxorubicin—liver cancer	0.00102	0.00146	CcSEcCtD
Betaxolol—Pharyngitis—Doxorubicin—liver cancer	0.00101	0.00145	CcSEcCtD
Betaxolol—Angiopathy—Epirubicin—liver cancer	0.001	0.00144	CcSEcCtD
Betaxolol—Immune system disorder—Epirubicin—liver cancer	0.000996	0.00143	CcSEcCtD
Betaxolol—Mediastinal disorder—Epirubicin—liver cancer	0.000994	0.00143	CcSEcCtD
Betaxolol—Chills—Epirubicin—liver cancer	0.00099	0.00142	CcSEcCtD
Betaxolol—Arrhythmia—Epirubicin—liver cancer	0.000985	0.00141	CcSEcCtD
Betaxolol—Visual impairment—Doxorubicin—liver cancer	0.000983	0.00141	CcSEcCtD
Betaxolol—Alopecia—Epirubicin—liver cancer	0.000975	0.0014	CcSEcCtD
Betaxolol—Mental disorder—Epirubicin—liver cancer	0.000966	0.00139	CcSEcCtD
Betaxolol—Malnutrition—Epirubicin—liver cancer	0.00096	0.00138	CcSEcCtD
Betaxolol—Erythema—Epirubicin—liver cancer	0.00096	0.00138	CcSEcCtD
Betaxolol—Eye disorder—Doxorubicin—liver cancer	0.000954	0.00137	CcSEcCtD
Betaxolol—Tinnitus—Doxorubicin—liver cancer	0.000951	0.00137	CcSEcCtD
Betaxolol—Flushing—Doxorubicin—liver cancer	0.000947	0.00136	CcSEcCtD
Betaxolol—Cardiac disorder—Doxorubicin—liver cancer	0.000947	0.00136	CcSEcCtD
Betaxolol—Tension—Epirubicin—liver cancer	0.000942	0.00135	CcSEcCtD
Betaxolol—Dysgeusia—Epirubicin—liver cancer	0.00094	0.00135	CcSEcCtD
Betaxolol—Nervousness—Epirubicin—liver cancer	0.000932	0.00134	CcSEcCtD
Betaxolol—Angiopathy—Doxorubicin—liver cancer	0.000926	0.00133	CcSEcCtD
Betaxolol—Muscle spasms—Epirubicin—liver cancer	0.000923	0.00132	CcSEcCtD
Betaxolol—Immune system disorder—Doxorubicin—liver cancer	0.000922	0.00132	CcSEcCtD
Betaxolol—Mediastinal disorder—Doxorubicin—liver cancer	0.00092	0.00132	CcSEcCtD
Betaxolol—Chills—Doxorubicin—liver cancer	0.000916	0.00131	CcSEcCtD
Betaxolol—Arrhythmia—Doxorubicin—liver cancer	0.000912	0.00131	CcSEcCtD
Betaxolol—Vision blurred—Epirubicin—liver cancer	0.000905	0.0013	CcSEcCtD
Betaxolol—Alopecia—Doxorubicin—liver cancer	0.000902	0.00129	CcSEcCtD
Betaxolol—Mental disorder—Doxorubicin—liver cancer	0.000894	0.00128	CcSEcCtD
Betaxolol—Ill-defined disorder—Epirubicin—liver cancer	0.000891	0.00128	CcSEcCtD
Betaxolol—Malnutrition—Doxorubicin—liver cancer	0.000888	0.00128	CcSEcCtD
Betaxolol—Erythema—Doxorubicin—liver cancer	0.000888	0.00128	CcSEcCtD
Betaxolol—Anaemia—Epirubicin—liver cancer	0.000887	0.00127	CcSEcCtD
Betaxolol—Tension—Doxorubicin—liver cancer	0.000872	0.00125	CcSEcCtD
Betaxolol—Dysgeusia—Doxorubicin—liver cancer	0.00087	0.00125	CcSEcCtD
Betaxolol—Malaise—Epirubicin—liver cancer	0.000866	0.00124	CcSEcCtD
Betaxolol—Nervousness—Doxorubicin—liver cancer	0.000863	0.00124	CcSEcCtD
Betaxolol—Vertigo—Epirubicin—liver cancer	0.000863	0.00124	CcSEcCtD
Betaxolol—Syncope—Epirubicin—liver cancer	0.000861	0.00124	CcSEcCtD
Betaxolol—Muscle spasms—Doxorubicin—liver cancer	0.000854	0.00123	CcSEcCtD
Betaxolol—Palpitations—Epirubicin—liver cancer	0.000848	0.00122	CcSEcCtD
Betaxolol—Loss of consciousness—Epirubicin—liver cancer	0.000844	0.00121	CcSEcCtD
Betaxolol—Cough—Epirubicin—liver cancer	0.000838	0.0012	CcSEcCtD
Betaxolol—Vision blurred—Doxorubicin—liver cancer	0.000837	0.0012	CcSEcCtD
Betaxolol—Ill-defined disorder—Doxorubicin—liver cancer	0.000824	0.00118	CcSEcCtD
Betaxolol—Anaemia—Doxorubicin—liver cancer	0.000821	0.00118	CcSEcCtD
Betaxolol—Arthralgia—Epirubicin—liver cancer	0.000817	0.00117	CcSEcCtD
Betaxolol—Myalgia—Epirubicin—liver cancer	0.000817	0.00117	CcSEcCtD
Betaxolol—Chest pain—Epirubicin—liver cancer	0.000817	0.00117	CcSEcCtD
Betaxolol—Anxiety—Epirubicin—liver cancer	0.000815	0.00117	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000812	0.00117	CcSEcCtD
Betaxolol—Discomfort—Epirubicin—liver cancer	0.000808	0.00116	CcSEcCtD
Betaxolol—Malaise—Doxorubicin—liver cancer	0.000801	0.00115	CcSEcCtD
Betaxolol—Dry mouth—Epirubicin—liver cancer	0.000799	0.00115	CcSEcCtD
Betaxolol—Vertigo—Doxorubicin—liver cancer	0.000798	0.00115	CcSEcCtD
Betaxolol—Syncope—Doxorubicin—liver cancer	0.000797	0.00114	CcSEcCtD
Betaxolol—Confusional state—Epirubicin—liver cancer	0.00079	0.00113	CcSEcCtD
Betaxolol—Palpitations—Doxorubicin—liver cancer	0.000785	0.00113	CcSEcCtD
Betaxolol—Oedema—Epirubicin—liver cancer	0.000784	0.00112	CcSEcCtD
Betaxolol—Loss of consciousness—Doxorubicin—liver cancer	0.000781	0.00112	CcSEcCtD
Betaxolol—Infection—Epirubicin—liver cancer	0.000778	0.00112	CcSEcCtD
Betaxolol—Cough—Doxorubicin—liver cancer	0.000775	0.00111	CcSEcCtD
Betaxolol—Shock—Epirubicin—liver cancer	0.000771	0.00111	CcSEcCtD
Betaxolol—Nervous system disorder—Epirubicin—liver cancer	0.000768	0.0011	CcSEcCtD
Betaxolol—Thrombocytopenia—Epirubicin—liver cancer	0.000767	0.0011	CcSEcCtD
Betaxolol—Tachycardia—Epirubicin—liver cancer	0.000765	0.0011	CcSEcCtD
Betaxolol—Skin disorder—Epirubicin—liver cancer	0.000761	0.00109	CcSEcCtD
Betaxolol—Hyperhidrosis—Epirubicin—liver cancer	0.000757	0.00109	CcSEcCtD
Betaxolol—Myalgia—Doxorubicin—liver cancer	0.000756	0.00109	CcSEcCtD
Betaxolol—Chest pain—Doxorubicin—liver cancer	0.000756	0.00109	CcSEcCtD
Betaxolol—Arthralgia—Doxorubicin—liver cancer	0.000756	0.00109	CcSEcCtD
Betaxolol—Anxiety—Doxorubicin—liver cancer	0.000754	0.00108	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000751	0.00108	CcSEcCtD
Betaxolol—Discomfort—Doxorubicin—liver cancer	0.000747	0.00107	CcSEcCtD
Betaxolol—Anorexia—Epirubicin—liver cancer	0.000747	0.00107	CcSEcCtD
Betaxolol—Dry mouth—Doxorubicin—liver cancer	0.00074	0.00106	CcSEcCtD
Betaxolol—Hypotension—Epirubicin—liver cancer	0.000732	0.00105	CcSEcCtD
Betaxolol—Confusional state—Doxorubicin—liver cancer	0.000731	0.00105	CcSEcCtD
Betaxolol—Oedema—Doxorubicin—liver cancer	0.000725	0.00104	CcSEcCtD
Betaxolol—Infection—Doxorubicin—liver cancer	0.00072	0.00103	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000714	0.00102	CcSEcCtD
Betaxolol—Shock—Doxorubicin—liver cancer	0.000713	0.00102	CcSEcCtD
Betaxolol—Nervous system disorder—Doxorubicin—liver cancer	0.000711	0.00102	CcSEcCtD
Betaxolol—Thrombocytopenia—Doxorubicin—liver cancer	0.00071	0.00102	CcSEcCtD
Betaxolol—Insomnia—Epirubicin—liver cancer	0.000709	0.00102	CcSEcCtD
Betaxolol—Tachycardia—Doxorubicin—liver cancer	0.000708	0.00102	CcSEcCtD
Betaxolol—Skin disorder—Doxorubicin—liver cancer	0.000704	0.00101	CcSEcCtD
Betaxolol—Paraesthesia—Epirubicin—liver cancer	0.000704	0.00101	CcSEcCtD
Betaxolol—Hyperhidrosis—Doxorubicin—liver cancer	0.000701	0.00101	CcSEcCtD
Betaxolol—Dyspnoea—Epirubicin—liver cancer	0.000699	0.001	CcSEcCtD
Betaxolol—Anorexia—Doxorubicin—liver cancer	0.000691	0.000992	CcSEcCtD
Betaxolol—Dyspepsia—Epirubicin—liver cancer	0.00069	0.00099	CcSEcCtD
Betaxolol—Decreased appetite—Epirubicin—liver cancer	0.000681	0.000978	CcSEcCtD
Betaxolol—Hypotension—Doxorubicin—liver cancer	0.000677	0.000972	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Epirubicin—liver cancer	0.000676	0.000971	CcSEcCtD
Betaxolol—Fatigue—Epirubicin—liver cancer	0.000676	0.00097	CcSEcCtD
Betaxolol—Pain—Epirubicin—liver cancer	0.00067	0.000962	CcSEcCtD
Betaxolol—Constipation—Epirubicin—liver cancer	0.00067	0.000962	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000661	0.000948	CcSEcCtD
Betaxolol—Insomnia—Doxorubicin—liver cancer	0.000656	0.000941	CcSEcCtD
Betaxolol—Paraesthesia—Doxorubicin—liver cancer	0.000651	0.000934	CcSEcCtD
Betaxolol—Dyspnoea—Doxorubicin—liver cancer	0.000646	0.000928	CcSEcCtD
Betaxolol—Feeling abnormal—Epirubicin—liver cancer	0.000646	0.000927	CcSEcCtD
Betaxolol—Dyspepsia—Doxorubicin—liver cancer	0.000638	0.000916	CcSEcCtD
Betaxolol—Decreased appetite—Doxorubicin—liver cancer	0.00063	0.000905	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000626	0.000898	CcSEcCtD
Betaxolol—Fatigue—Doxorubicin—liver cancer	0.000625	0.000897	CcSEcCtD
Betaxolol—Urticaria—Epirubicin—liver cancer	0.000622	0.000894	CcSEcCtD
Betaxolol—Pain—Doxorubicin—liver cancer	0.00062	0.00089	CcSEcCtD
Betaxolol—Constipation—Doxorubicin—liver cancer	0.00062	0.00089	CcSEcCtD
Betaxolol—Body temperature increased—Epirubicin—liver cancer	0.000619	0.000889	CcSEcCtD
Betaxolol—Feeling abnormal—Doxorubicin—liver cancer	0.000597	0.000858	CcSEcCtD
Betaxolol—Hypersensitivity—Epirubicin—liver cancer	0.000577	0.000829	CcSEcCtD
Betaxolol—Urticaria—Doxorubicin—liver cancer	0.000576	0.000827	CcSEcCtD
Betaxolol—Body temperature increased—Doxorubicin—liver cancer	0.000573	0.000823	CcSEcCtD
Betaxolol—Asthenia—Epirubicin—liver cancer	0.000562	0.000807	CcSEcCtD
Betaxolol—Pruritus—Epirubicin—liver cancer	0.000554	0.000796	CcSEcCtD
Betaxolol—Diarrhoea—Epirubicin—liver cancer	0.000536	0.00077	CcSEcCtD
Betaxolol—Hypersensitivity—Doxorubicin—liver cancer	0.000534	0.000767	CcSEcCtD
Betaxolol—Asthenia—Doxorubicin—liver cancer	0.00052	0.000747	CcSEcCtD
Betaxolol—Dizziness—Epirubicin—liver cancer	0.000518	0.000744	CcSEcCtD
Betaxolol—Pruritus—Doxorubicin—liver cancer	0.000513	0.000736	CcSEcCtD
Betaxolol—Vomiting—Epirubicin—liver cancer	0.000498	0.000715	CcSEcCtD
Betaxolol—Diarrhoea—Doxorubicin—liver cancer	0.000496	0.000712	CcSEcCtD
Betaxolol—Rash—Epirubicin—liver cancer	0.000494	0.000709	CcSEcCtD
Betaxolol—Dermatitis—Epirubicin—liver cancer	0.000494	0.000709	CcSEcCtD
Betaxolol—Headache—Epirubicin—liver cancer	0.000491	0.000705	CcSEcCtD
Betaxolol—Dizziness—Doxorubicin—liver cancer	0.000479	0.000688	CcSEcCtD
Betaxolol—Nausea—Epirubicin—liver cancer	0.000465	0.000668	CcSEcCtD
Betaxolol—Vomiting—Doxorubicin—liver cancer	0.000461	0.000662	CcSEcCtD
Betaxolol—Rash—Doxorubicin—liver cancer	0.000457	0.000656	CcSEcCtD
Betaxolol—Dermatitis—Doxorubicin—liver cancer	0.000457	0.000656	CcSEcCtD
Betaxolol—Headache—Doxorubicin—liver cancer	0.000454	0.000652	CcSEcCtD
Betaxolol—Nausea—Doxorubicin—liver cancer	0.000431	0.000618	CcSEcCtD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—liver cancer	0.000164	0.00222	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—EPT1—liver cancer	0.000163	0.00221	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—liver cancer	0.000159	0.00216	CbGpPWpGaD
Betaxolol—CYP2D6—Biological oxidations—GGT1—liver cancer	0.000156	0.00211	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—liver cancer	0.000154	0.00209	CbGpPWpGaD
Betaxolol—CYP1A2—Biological oxidations—CYP2E1—liver cancer	0.000144	0.00195	CbGpPWpGaD
Betaxolol—CYP1A2—Metapathway biotransformation—CYP2E1—liver cancer	0.000142	0.00192	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—TRIO—liver cancer	0.000142	0.00192	CbGpPWpGaD
Betaxolol—CYP2D6—Biological oxidations—GSTP1—liver cancer	0.00014	0.0019	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—liver cancer	0.000139	0.00188	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—TRIO—liver cancer	0.000139	0.00188	CbGpPWpGaD
Betaxolol—CYP2D6—Metapathway biotransformation—GSTP1—liver cancer	0.000138	0.00187	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—CCR4—liver cancer	0.000136	0.00184	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—CCR4—liver cancer	0.000133	0.0018	CbGpPWpGaD
Betaxolol—CYP1A2—Biological oxidations—GGT1—liver cancer	0.000132	0.00179	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—TRIO—liver cancer	0.000129	0.00174	CbGpPWpGaD
Betaxolol—CYP2D6—Biological oxidations—GSTM1—liver cancer	0.000129	0.00174	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—MYC—liver cancer	0.000128	0.00173	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—liver cancer	0.000128	0.00173	CbGpPWpGaD
Betaxolol—CYP2D6—Metapathway biotransformation—GSTM1—liver cancer	0.000127	0.00172	CbGpPWpGaD
Betaxolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—F2—liver cancer	0.000126	0.00171	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—TRIO—liver cancer	0.000126	0.00171	CbGpPWpGaD
Betaxolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—F2—liver cancer	0.000124	0.00167	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—CCR4—liver cancer	0.000124	0.00167	CbGpPWpGaD
Betaxolol—CYP2D6—Biological oxidations—CYP1A1—liver cancer	0.000122	0.00165	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—CCR4—liver cancer	0.000121	0.00164	CbGpPWpGaD
Betaxolol—CYP2D6—Metapathway biotransformation—CYP1A1—liver cancer	0.00012	0.00163	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—TNF—liver cancer	0.000119	0.00161	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—liver cancer	0.000119	0.00161	CbGpPWpGaD
Betaxolol—CYP1A2—Biological oxidations—GSTP1—liver cancer	0.000119	0.00161	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—liver cancer	0.000118	0.0016	CbGpPWpGaD
Betaxolol—CYP1A2—Metapathway biotransformation—GSTP1—liver cancer	0.000117	0.00158	CbGpPWpGaD
Betaxolol—CYP1A2—Biological oxidations—GSTM1—liver cancer	0.000109	0.00148	CbGpPWpGaD
Betaxolol—CYP1A2—Metapathway biotransformation—GSTM1—liver cancer	0.000108	0.00146	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	0.000105	0.00142	CbGpPWpGaD
Betaxolol—CYP1A2—Biological oxidations—CYP1A1—liver cancer	0.000103	0.0014	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—SHC3—liver cancer	0.000103	0.00139	CbGpPWpGaD
Betaxolol—CYP1A2—Metapathway biotransformation—CYP1A1—liver cancer	0.000102	0.00138	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	0.000102	0.00137	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—liver cancer	0.000101	0.00136	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—SHC3—liver cancer	0.000101	0.00136	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—F2—liver cancer	9.63e-05	0.0013	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—F2—liver cancer	9.42e-05	0.00127	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—UGDH—liver cancer	9.14e-05	0.00124	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—EPT1—liver cancer	8.59e-05	0.00116	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—TAT—liver cancer	8.14e-05	0.0011	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—FST—liver cancer	7.98e-05	0.00108	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—PRKCE—liver cancer	7.84e-05	0.00106	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—FST—liver cancer	7.81e-05	0.00106	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	7.76e-05	0.00105	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—UGDH—liver cancer	7.74e-05	0.00105	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—PRKCE—liver cancer	7.67e-05	0.00104	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—TRIO—liver cancer	7.61e-05	0.00103	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—TRIO—liver cancer	7.45e-05	0.00101	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CCR4—liver cancer	7.3e-05	0.000988	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—EPT1—liver cancer	7.28e-05	0.000984	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CCR4—liver cancer	7.14e-05	0.000966	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—PRKCE—liver cancer	7.12e-05	0.000963	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—PRKCE—liver cancer	6.96e-05	0.000942	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—CSF2—liver cancer	6.93e-05	0.000938	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—TAT—liver cancer	6.9e-05	0.000933	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	6.78e-05	0.000918	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—CSF2—liver cancer	6.78e-05	0.000917	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—CSF2—liver cancer	6.3e-05	0.000852	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—CSF2—liver cancer	6.16e-05	0.000833	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—ADAM17—liver cancer	5.77e-05	0.000781	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—ADAM17—liver cancer	5.65e-05	0.000764	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CPT1B—liver cancer	5.53e-05	0.000749	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GLUL—liver cancer	5.53e-05	0.000749	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—F2—liver cancer	5.44e-05	0.000736	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PSMA4—liver cancer	5.43e-05	0.000734	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PSMD10—liver cancer	5.43e-05	0.000734	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—NR1H4—liver cancer	5.34e-05	0.000722	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—F2—liver cancer	5.32e-05	0.00072	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PSMD10—liver cancer	5.31e-05	0.000718	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PSMA4—liver cancer	5.31e-05	0.000718	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GSTA3—liver cancer	5.25e-05	0.00071	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—PIK3CG—liver cancer	5.21e-05	0.000704	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—PIK3CG—liver cancer	5.09e-05	0.000689	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—liver cancer	5.08e-05	0.000687	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—F2—liver cancer	4.94e-05	0.000668	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—F2—liver cancer	4.83e-05	0.000654	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GSTA4—liver cancer	4.8e-05	0.000649	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—PIK3CG—liver cancer	4.73e-05	0.00064	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GLUL—liver cancer	4.69e-05	0.000634	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CPT1B—liver cancer	4.69e-05	0.000634	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GSTA2—liver cancer	4.68e-05	0.000633	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—PIK3CG—liver cancer	4.62e-05	0.000626	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—PIK3CD—liver cancer	4.58e-05	0.000619	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—NR1H4—liver cancer	4.52e-05	0.000612	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GSTA1—liver cancer	4.51e-05	0.00061	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—PIK3CD—liver cancer	4.48e-05	0.000606	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—NAT2—liver cancer	4.46e-05	0.000604	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTA3—liver cancer	4.44e-05	0.000601	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ALDOB—liver cancer	4.28e-05	0.000579	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PRKCE—liver cancer	4.2e-05	0.000569	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—PIK3CD—liver cancer	4.16e-05	0.000562	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PRKCE—liver cancer	4.11e-05	0.000556	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CRABP1—liver cancer	4.08e-05	0.000552	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—PIK3CD—liver cancer	4.07e-05	0.00055	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTA4—liver cancer	4.07e-05	0.00055	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—PIK3CB—liver cancer	3.99e-05	0.00054	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—IGF2—liver cancer	3.98e-05	0.000539	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	3.97e-05	0.000538	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTA2—liver cancer	3.96e-05	0.000536	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—PIK3CB—liver cancer	3.9e-05	0.000528	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—IGF2—liver cancer	3.9e-05	0.000527	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTA1—liver cancer	3.82e-05	0.000517	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—NAT2—liver cancer	3.78e-05	0.000511	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CSF2—liver cancer	3.72e-05	0.000503	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—RAF1—liver cancer	3.71e-05	0.000502	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—H2AFX—liver cancer	3.67e-05	0.000496	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—IL2—liver cancer	3.66e-05	0.000496	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CSF2—liver cancer	3.64e-05	0.000492	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—liver cancer	3.63e-05	0.000492	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—RAF1—liver cancer	3.63e-05	0.000491	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ALDOB—liver cancer	3.62e-05	0.00049	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—PIK3CB—liver cancer	3.62e-05	0.00049	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—H2AFX—liver cancer	3.59e-05	0.000485	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—IL2—liver cancer	3.58e-05	0.000485	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—HPGDS—liver cancer	3.57e-05	0.000482	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—PIK3CB—liver cancer	3.54e-05	0.000479	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CRABP1—liver cancer	3.46e-05	0.000468	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—IL2—liver cancer	3.33e-05	0.00045	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—TERT—liver cancer	3.31e-05	0.000448	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—IL2—liver cancer	3.25e-05	0.00044	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—TERT—liver cancer	3.24e-05	0.000439	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PSMA4—liver cancer	3.18e-05	0.00043	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PSMD10—liver cancer	3.18e-05	0.00043	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	3.11e-05	0.000421	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GOT2—liver cancer	3.09e-05	0.000418	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—KDR—liver cancer	3.03e-05	0.00041	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—HPGDS—liver cancer	3.02e-05	0.000409	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MAPK14—liver cancer	3.01e-05	0.000407	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—liver cancer	3e-05	0.000406	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—KDR—liver cancer	2.97e-05	0.000401	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—ESR1—liver cancer	2.95e-05	0.0004	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MAPK14—liver cancer	2.95e-05	0.000399	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—F2—liver cancer	2.92e-05	0.000395	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CYP2E1—liver cancer	2.91e-05	0.000393	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—ESR1—liver cancer	2.89e-05	0.000391	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—F2—liver cancer	2.85e-05	0.000386	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—APC—liver cancer	2.79e-05	0.000378	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PIK3CG—liver cancer	2.79e-05	0.000378	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	2.74e-05	0.00037	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—APC—liver cancer	2.73e-05	0.00037	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PIK3CG—liver cancer	2.73e-05	0.00037	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CYCS—liver cancer	2.72e-05	0.000368	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—ALB—liver cancer	2.7e-05	0.000365	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PSMA4—liver cancer	2.69e-05	0.000364	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PSMD10—liver cancer	2.69e-05	0.000364	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GGT1—liver cancer	2.67e-05	0.000361	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GOT1—liver cancer	2.67e-05	0.000361	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—BRAF—liver cancer	2.62e-05	0.000355	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GOT2—liver cancer	2.62e-05	0.000354	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—BRAF—liver cancer	2.57e-05	0.000347	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CYP2E1—liver cancer	2.46e-05	0.000333	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PIK3CD—liver cancer	2.45e-05	0.000332	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—PIK3CA—liver cancer	2.43e-05	0.000329	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—SERPINE1—liver cancer	2.43e-05	0.000328	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—KRAS—liver cancer	2.4e-05	0.000325	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PIK3CD—liver cancer	2.4e-05	0.000325	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GSTP1—liver cancer	2.4e-05	0.000324	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	2.38e-05	0.000323	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—PIK3CA—liver cancer	2.38e-05	0.000322	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—SERPINE1—liver cancer	2.38e-05	0.000321	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—HMOX1—liver cancer	2.36e-05	0.00032	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—KRAS—liver cancer	2.35e-05	0.000318	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CYCS—liver cancer	2.3e-05	0.000312	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GGT1—liver cancer	2.26e-05	0.000306	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GOT1—liver cancer	2.26e-05	0.000306	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—PIK3CA—liver cancer	2.21e-05	0.000299	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GSTM1—liver cancer	2.2e-05	0.000298	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—RAF1—liver cancer	2.19e-05	0.000296	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—PIK3CA—liver cancer	2.16e-05	0.000292	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—RAF1—liver cancer	2.14e-05	0.00029	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MTOR—liver cancer	2.14e-05	0.000289	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PIK3CB—liver cancer	2.14e-05	0.000289	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MTOR—liver cancer	2.09e-05	0.000283	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PIK3CB—liver cancer	2.09e-05	0.000283	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CYP1A1—liver cancer	2.09e-05	0.000283	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—HRAS—liver cancer	2.04e-05	0.000276	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTP1—liver cancer	2.03e-05	0.000275	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CDKN1B—liver cancer	2.01e-05	0.000272	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—HMOX1—liver cancer	2e-05	0.000271	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—HRAS—liver cancer	2e-05	0.00027	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—AKT1—liver cancer	1.99e-05	0.000269	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CASP3—liver cancer	1.97e-05	0.000266	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—IL2—liver cancer	1.97e-05	0.000266	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CDKN1B—liver cancer	1.96e-05	0.000266	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—IL6—liver cancer	1.96e-05	0.000265	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—MTHFR—liver cancer	1.95e-05	0.000263	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—AKT1—liver cancer	1.94e-05	0.000263	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CASP3—liver cancer	1.93e-05	0.00026	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—IL2—liver cancer	1.92e-05	0.00026	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CCND1—liver cancer	1.92e-05	0.000259	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—IL6—liver cancer	1.91e-05	0.000259	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—JUN—liver cancer	1.91e-05	0.000259	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PPARA—liver cancer	1.91e-05	0.000258	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CTNNB1—liver cancer	1.9e-05	0.000257	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CCND1—liver cancer	1.87e-05	0.000254	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—JUN—liver cancer	1.87e-05	0.000253	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTM1—liver cancer	1.87e-05	0.000253	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MMP9—liver cancer	1.86e-05	0.000252	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CTNNB1—liver cancer	1.86e-05	0.000251	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CDKN1A—liver cancer	1.85e-05	0.000251	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MMP9—liver cancer	1.82e-05	0.000246	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CDKN1A—liver cancer	1.81e-05	0.000245	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MAPK8—liver cancer	1.81e-05	0.000245	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—AKT1—liver cancer	1.8e-05	0.000244	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CYP1A1—liver cancer	1.77e-05	0.000239	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MAPK8—liver cancer	1.77e-05	0.000239	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—AKT1—liver cancer	1.76e-05	0.000239	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—VEGFA—liver cancer	1.67e-05	0.000226	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—STAT3—liver cancer	1.65e-05	0.000224	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—MTHFR—liver cancer	1.65e-05	0.000223	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PIK3CG—liver cancer	1.64e-05	0.000221	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—VEGFA—liver cancer	1.63e-05	0.000221	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PPARA—liver cancer	1.62e-05	0.000219	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—STAT3—liver cancer	1.62e-05	0.000219	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PPARG—liver cancer	1.58e-05	0.000214	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MYC—liver cancer	1.54e-05	0.000208	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—TGFB1—liver cancer	1.53e-05	0.000207	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MYC—liver cancer	1.5e-05	0.000203	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—TGFB1—liver cancer	1.5e-05	0.000203	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	1.45e-05	0.000197	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PIK3CD—liver cancer	1.44e-05	0.000195	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—KRAS—liver cancer	1.42e-05	0.000192	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ALB—liver cancer	1.42e-05	0.000192	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—KRAS—liver cancer	1.39e-05	0.000188	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PIK3CG—liver cancer	1.39e-05	0.000188	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PPARG—liver cancer	1.34e-05	0.000181	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PIK3CA—liver cancer	1.3e-05	0.000176	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PIK3CA—liver cancer	1.28e-05	0.000173	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—TP53—liver cancer	1.26e-05	0.000171	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PIK3CB—liver cancer	1.25e-05	0.00017	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—TP53—liver cancer	1.23e-05	0.000167	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PIK3CD—liver cancer	1.22e-05	0.000165	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—HRAS—liver cancer	1.21e-05	0.000163	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ALB—liver cancer	1.2e-05	0.000163	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—HRAS—liver cancer	1.18e-05	0.00016	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—IL6—liver cancer	1.16e-05	0.000156	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—IL6—liver cancer	1.13e-05	0.000153	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—AKT1—liver cancer	1.07e-05	0.000144	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PIK3CB—liver cancer	1.06e-05	0.000144	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—AKT1—liver cancer	1.04e-05	0.000141	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—PIK3CA—liver cancer	7.64e-06	0.000103	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—PIK3CA—liver cancer	6.47e-06	8.76e-05	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—AKT1—liver cancer	6.24e-06	8.45e-05	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—AKT1—liver cancer	5.29e-06	7.15e-05	CbGpPWpGaD
